Metabolic syndrome Nutritional, Metabolic, Endocrine Metabolic syndrome
Conditions
Interventions
Treatment with atorvastatin 10 mg per day versus placebo.
Sponsors
Royal Group of Hospitals Trust (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age 35 - 63 years 2. Metabolic syndrome as defined by the International Diabetes Federation, central obesity plus two of the following: 2.1. Hypertension 2.2. Glucose intolerance 2.3. Low levels of high-density lipoprotein cholesterol (HDL-C) 2.4. Hypertriglyceridemia Control subjects must have none of these features.
Exclusion criteria
Exclusion criteria: 1. Pre-existing indication for lipid-lowering therapy, or history of intolerance of these agents 2. Use of insulin or hormone replacement therapy 3. History of liver or muscle disease 4. Impaired renal function 5. Potential for pregnancy (females) 6. Total cholesterol greater than 6.5 mmol/l or less than 4 mmol/l
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Measurement of expression of other molecules (e.g. cell adhesion molecules) involved in atherosclerosis in serum, monocytes and human endothelial cells exposed to patient serum | — |
Primary
| Measure | Time frame |
|---|---|
| Measurement of monocyte response to chemotaxins in vitro (the chemotactic index) | — |
Countries
United Kingdom
Outcome results
None listed